“Dicerna has achieved significant milestones in the first half of 2014 including completing a very successful initial public offering in January and initiating our first in-human Phase 1 clinical trial of DCR-MYC, our dicer substrate RNA interference candidate (DsiRNA), in patients with solid tumors, multiple myeloma, or lymphoma,” said
Dr. Fambrough and the Dicerna management team will ring the closing bell on
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.
Cautionary Contact on Forward-looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading "Risk Factors" included in our Form 10-Q dated
LaVoie Health Science
Most Popular Stories
- National Retail Federation Reduces Sales Forecast
- Hispanic Leader Goes the Extra Mile
- Xavier Gutierrez Appointed to Bank Board
- Ted Cruz: Why Did FAA Ban Flights to Israel?
- Honda' s Accord Plug-in Hybrid Is a Fuel Miser
- Morgan Stanley Ponies Up $275 Million to Settle SEC Charges
- Stop-Start Engines Save Gas, Reduce Emissions
- Long-term Strengths Emerge in U.S. Economy
- Risks of Layoffs Becoming Rarer in U.S.
- Weekly Jobless Claims Drop to Lowest Level in 8 Years